AZD4573 is a potent and selective CDK9 inhibitor with an IC50 below 4 nM, designed for transient target engagement. It is utilized in hematologic malignancy research, demonstrating activity in both in vitro assays and in vivo xenograft models for cancers like acute myeloid leukemia.